On outside of the united states (ous) customer observed non-reactive atellica im hiv ag/ab combo (chiv) results on a patient compared to the reactive result obtain using two alternate test methods.Siemens investigated the event.Quality control (qc) was in range when the sample was tested.No other samples were affected, and the result was reproducibly non-reactive on atellica im chiv.No sample was remaining for further testing by siemens.The specimen was from an infant from an hiv positive mother.The limitations section of the instructions for use (ifu) states: "the calculated values for anti-hiv and/or p24 antigen in a given specimen as determined by assays from different manufacturers can vary due to differences in assay methods and reagent specificity.The results reported by the laboratory to the physician must include the identity of the assay used.Values obtained with different assay methods cannot be used interchangeably.The reported antibody level and/or p24 antigen cannot be correlated to an endpoint titer."the performance of the assay has not been established with infants." the interpretation of results section of the ifu states: "results of this assay should always be interpreted in conjunction with the patient¿s medical history, clinical presentation, and other findings." based on the investigation, no product performance issue was identified.The customer is operational.Section g4 lists the pma/510(k)number of similar us product (siemens material number 10995459).
|